InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.…
InfuSystems Holdings Inc (INFU) (Q3 2026) Earnings Call Highlights: Record Revenue, Wound Care ...
InfuSystem Holdings (NYSEAMERICAN: INFU) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 461 employees.
The shares were at 14.35 USD on 20 November 2026, up 37.3% over 52 weeks. Its 52-week range is 7.290 USD to 15.42 USD: the price is 6.9% below the high and 96.8% above the low.
At a market capitalisation of 287.48M USD, it trades at 32.6 times trailing earnings and 25.6 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 28% for INFU.
InfuSystem Holdings reports return on equity of 11.6%, an operating margin of 8.4% and revenue up 3.0% year over year.
Its debt exceeds its cash by 14.77M USD, a debt-to-equity ratio of 0.40. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 18.50 USD is 28.9% above the current price. The next earnings report is expected on 23 February 2027.